Adjunctive interventions in myocardial infarction: The role of statin therapy

Current Atherosclerosis Reports

Volumn 10, Issue 2, 2008, Pages 142-148

  Jones, Peter H ^b   Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE DRUG ADMINISTRATION; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DYSLIPIDEMIA; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; PATHOPHYSIOLOGY; REVIEW; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY OCCLUSION; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 41749104872     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0021-3     Document Type: Review

References (36)

1. Davidson MH, Robinson JG: Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother 2006, 7:1701-1714.
2. Gossl M, Versari D, Hildebrandt H, et al.: Vulnerable plaque: detection and management. Med Clin North Am 2007, 91:573-601; ix-x.
3. Renault MA, Losordo DW: The matrix revolutions: matrix metalloproteinase, vasculogenesis, and ischemic tissue repair. Circ Res 2007,100:749-750.
4. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006, 98(12A):3Q-9Q.
5. Brueckmann M, Bertsch T, Lang S, et al.: Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clin Chem Lab Med 2004, 42:1132-1139.
6. Albert MA, Ridker PM: The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1999, 1:99-104.
7. Devaraj S, Do Clos TW, Jialal I: Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005, 25:1359-1363.
8. Verma S, Wang CH, Li SH, et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
9. Tilley R, Mackman N: Tissue factor in heimostasis and thrombosis. Semin Thromb Hemost 2006, 32:5-10.
10. Asselbergs FW, Williams SM, Hebert PR, et al.: Genderspecific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. J Thromb Haemost 2007, 5:313-320.
11. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
12. Crisby M, Nordin- Fredriksson G, Shah PK, et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
13. Ridker PM: High-sensitivity C-reactive protein, inflammation' and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004, 148(Suppl 1):S19-S26.
14. Inoue I, Goto S, Mizotani K, et al.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000, 67:863-876.
15. Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 2001, 89:1092-1103.
16. Waehre T, Yndestad A, Smith C, et al.: Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004, 109:1966-1972.
17. Kavsak PA, MacRae AR, Newman AM, et al.: Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem 2007, 40(5-6):326-329.
18. Devaraj S, Rogers J, Jialal I: Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007, 9:33-41.
19. Greenwood J, Mason JC: Statins and the vascular endothelial inflammatory response. Trends Immunol 2007, 28:88-98.
20. Fichtlscherer S, Rosenberger G, Walter DH, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000-1006.
21. Karatzis EN, Ikonomidis I, Vamvakou GD, et al.: Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006, 98:1424-1428.
22. Wassmann S, Ribaudo N, Faul A, et al.: Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/d1. Am J Cardiol 2004, 93:84-88.
23. Hill JM, Zalos G, Halcox JP, et al.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
24. Undas A, Celinska-Lowenhoff M, Kaczor M, Musial J: New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004, 91:1065-1077.
25. Krysiak R, Okopien B, Herman Z: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003, 63:1821-1854.
26. Spencer FA, Fonarow GC, Frederick PD, et al.: Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med 2004, 164:2162-2168.
27. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452.
28. McGowan MP: There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004, 110:2333-2335.
29. Thompson PL, Meredith I, Amerena J, et al.: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 2004, 148:e2.
30. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
31. Liem AH, van Boven AJ, Veeger NJ, et al.: Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Fur Heart J 2002, 23:1931-1937.
32. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
34. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
35. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
36. Smith SC Jr, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.